Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 2, 2008, Pages 253-263

  Husarik, Daniela B ^a   Miralbell, Raymond ^b   Dubs, Markus ^c   John, Hubert ^d   Giger, Olivier T ^a   Gelet, Albert ^e   Cservenyàk, Tibor ^a   Hany, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Spital Uster   (Switzerland)

^d KLINIK HIRSLANDEN   (Switzerland)

^e EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

18F Choline; Initial staging; PET CT; Prostate cancer; Recurrence

Indexed keywords

BICALUTAMIDE; CHOLINE F 18; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BONE METASTASIS; BONE SCINTISCANNING; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG SENSITIVITY; DRUG UPTAKE; EVALUATION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHADENECTOMY; MALE; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RECURRENT DISEASE;

AGED; CHOLINE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 38349088040     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0552-9     Document Type: Article

References (26)

1. Jemal A, Murray T, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics 2005. CA Cancer J Clin 2005; 55:10-30.
2. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H. EAU guidelines on prostate cancer. Eur Urol 2005; 48:546-51.
3. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42:1S-93S.
4. Hautzel H, Muller-Mattheis V, Herzog H, Roden W, Coenen HH,. Ackermann R, et al. The (11C) acetate positron emission tomography in prostatic carcinoma. New prospects in metabolic imaging. Urologe A 2002; 41:569-76.
5. de Jong IJ, Pruim J, Elsinga PH, Jongen MM, Mensink HJ, Vaalburg W. Visualisation of bladder cancer using (11)C-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging 2002; 29:1283-8.
6. Hara T, Kosaka N, Kishi H. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002; 43:187-99.
7. DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN, Polascik TJ, Price DT. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61:110-7.
8. Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000; 27:1415-9.
9. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39:990-5.
10. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, Borsatti E, Drigo A, Trovo MG. [18]F-fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33:1387-1398.
11. Schmid DT, John H, Zweifel R, Cservenyak T, Wetsera G, Goerres GW, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005; 235:623-8.
12. Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E, et al. [11]C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006; 176:954-60.
13. Reske SN, Blumstein NM, Neumaier B, Gottfried HW. et al. Imaging prostate cancer with 11C-Choline PET/CT. J Nucl Med 2006; 47:1249-54.
14. Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein P, Lieskovsky G, Skinner DG, Coteet RJ. Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 2006; 24:2735-42.
15. Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006; 68:121-5.
16. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Is pelvic lymph node dissection necessary in patients with a serum PSA<10 ng/ml undergoing radical prostatectomy for prostate cancer? Eur Urol 2006; 50:272-9.
17. Weckermann D, Goppelt M, Dorn R, Wawroschek F, Harzmann R. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of ≤10 ng/mL and biopsy Gleason score of ≤6, and their influence on PSA progression-free survival after radical prostatectomy. BJU Int 2006; 97:1173-8.
18. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006; 36:73-92.
19. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003; 61:365-9.
20. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348:2491-9.
21. Cornud F, Bellin MF, Portalez D. MRI and staging evaluation of prostate cancer. J Radiol 2006; 87:228-43.
22. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, Hricak H. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004; 231:379-85.
23. Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, Langsteger W. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 2006; 8:43-8.
24. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168:273-80.
25. Poissonnier L, Chapelon JY, Rouviere O, et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2006; 51:381-387.
26. Hacker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006; 176:2014-18; discussion 2018-19.